Dysregulation of glutamatergic circuits in the brain is involved in the development of centralized chronic pain.
NYX-2925 is in late stage clinical development across two chronic pain indications – Painful Diabetic Peripheral Neuropathy and Fibromyalgia.
Dysregulation of NMDA receptor-mediated processes may underlie the development and / or persistence of PTSD.
NYX-783 demonstrated clear signals of symptom reduction with a favorable tolerability profile in a Phase 2 exploratory study in patients with PTSD consisting of only 4 weeks of treatment with NYX-783; A registration-supportive study evaluating NYX-783 in patients with PTSD is expected to begin in 2021.
NMDA receptors are critical to learning and memory processes and their dysregulation has been implicated across numerous conditions involving cognitive impairment.
NYX-458 is under evaluation in a first-in-patient Phase 2 study in cognitive impairment associated with Parkinson’s disease.